Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06979596CT.gov A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | — | Recruiting | — | — | — |
NCT06251310CT.gov SW-682 in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05279300CT.gov A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | — | Recruiting | — | — | — |
NCT05145400CT.gov Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT03324113CT.gov Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | — | Completed | — | — | — |
NCT02265510CT.gov An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02257476CT.gov Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02057380CT.gov A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | — | Completed | — | — | — |
NCT01953783CT.gov Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | — | Completed | — | — | — |
NCT01983969CT.gov Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT01830816CT.gov Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | — | Completed | — | — | — |
NCT01912222CT.gov Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | — | Completed | — | — | — |
NCT01200004CT.gov Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide | — | Terminated | — | — | — |
NCT01183663CT.gov Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | — | Completed | — | — | — |
NCT01284335CT.gov A Safety Study in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00840385CT.gov Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) | — | Unknown | — | — | — |
NCT00629473CT.gov Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT00250718CT.gov Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Merck Sharp & Dohme LLC | P3 | B · 62 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →